Profile data is unavailable for this security.
About the company
Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The Company is focused on developing cell therapies for patients suffering from autoimmune diseases. The Company's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). It intends to develop KYV-101 in two areas of autoimmune disease: rheumatology and neurology. Its initial rheumatology development focus is on lupus nephritis, and systemic sclerosis. It is also actively developing an allogeneic, off-the-shelf approach to further broaden patient access. Its research-stage programs are focused on developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, and extend beyond CD19 CAR-T approaches, including regulatory T cells, or T-regs, and novel humanized CAR constructs developed by it for use in autoimmune diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-110.66m
- Incorporated2018
- Employees119.00
- LocationKyverna Therapeutics Inc5980 Horton Street, Suite 550EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 626-8331
- Fax+1 (302) 655-5049
- Websitehttps://kyvernatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actuate Therapeutics Inc | -100.00bn | -100.00bn | 167.58m | 11.00 | -- | 31.27 | -- | -- | -- | -- | -- | 0.2744 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0703 | -- | -- | -- | -22.74 | -- | -- | -- |
| Verastem Inc | 10.00m | -93.45m | 168.68m | 73.00 | -- | 13.80 | -- | 16.87 | -3.18 | -3.18 | 0.3311 | 0.8002 | 0.0661 | -- | 100.00 | 136,986.30 | -61.78 | -62.70 | -77.44 | -75.18 | -- | -- | -934.54 | -406.17 | -- | -- | 0.5579 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -10.50m | 168.91m | 3.00 | -- | 33.90 | -- | -- | -0.8111 | -0.8111 | 0.00 | 0.3791 | 0.00 | -- | -- | 0.00 | -140.17 | -36.43 | -151.72 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Heron Therapeutics Inc | 137.74m | -27.97m | 169.87m | 126.00 | -- | -- | -- | 1.23 | -0.1841 | -0.1841 | 0.9067 | -0.2637 | 0.6122 | 0.871 | 2.11 | 1,093,151.00 | -12.43 | -53.55 | -19.65 | -71.24 | 72.19 | 52.52 | -20.30 | -170.12 | 1.74 | -- | 1.36 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Adaptimmune Therapeutics PLC - ADR | 175.04m | -44.52m | 169.99m | 449.00 | -- | 2.12 | -- | 0.9712 | -0.2126 | -0.2126 | 0.7109 | 0.3128 | 0.5701 | -- | 26.34 | 389,846.30 | -14.50 | -41.19 | -18.73 | -48.21 | -- | -- | -25.43 | -714.26 | 3.82 | -- | 0.384 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -21.71m | 171.85m | 18.00 | -- | 3.58 | -- | -- | -0.5527 | -0.5527 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | -39.23 | -45.38 | -41.66 | -48.24 | -- | -- | -- | -- | -- | -- | 0.0055 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Galectin Therapeutics Inc | 0.00 | -45.23m | 175.31m | 14.00 | -- | -- | -- | -- | -0.7284 | -0.7284 | 0.00 | -1.48 | 0.00 | -- | -- | 0.00 | -176.31 | -92.08 | -587.13 | -121.97 | -- | -- | -- | -- | -- | -7.18 | 8.66 | -- | -- | -- | -15.26 | -- | -- | -- |
| Tenaya Therapeutics Inc | 0.00 | -117.23m | 175.87m | 140.00 | -- | 1.56 | -- | -- | -1.44 | -1.44 | 0.00 | 1.42 | 0.00 | -- | -- | 0.00 | -70.20 | -- | -78.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Nkarta Inc | 0.00 | -110.61m | 176.42m | 159.00 | -- | 0.4095 | -- | -- | -1.87 | -1.87 | 0.00 | 6.11 | 0.00 | -- | -- | 0.00 | -23.59 | -32.39 | -24.86 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Caribou Biosciences Inc | 11.48m | -148.12m | 177.48m | 158.00 | -- | 0.6312 | -- | 15.47 | -1.65 | -1.65 | 0.128 | 3.11 | 0.0286 | -- | 5.08 | 72,626.59 | -36.94 | -- | -39.76 | -- | -- | -- | -1,290.81 | -- | -- | -1,321.46 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -110.66m | 177.77m | 119.00 | -- | 0.5875 | -- | -- | -2.50 | -2.50 | 0.00 | 7.01 | 0.00 | -- | -- | 0.00 | -51.27 | -- | -57.66 | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Inozyme Pharma Inc | 0.00 | -96.49m | 179.23m | 59.00 | -- | 2.16 | -- | -- | -1.55 | -1.55 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -55.29 | -45.00 | -60.60 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3554 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Nektar Therapeutics | 93.14m | -168.30m | 184.46m | 137.00 | -- | 3.77 | -- | 1.98 | -0.8371 | -0.8371 | 0.4634 | 0.265 | 0.2483 | 3.96 | 84.52 | 679,832.10 | -44.87 | -31.02 | -53.39 | -34.63 | 67.80 | 78.04 | -180.70 | -372.21 | 4.24 | -15.53 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Fulcrum Therapeutics Inc | 80.87m | -17.91m | 186.58m | 76.00 | -- | 0.6268 | -- | 2.31 | -0.3098 | -0.3098 | 1.29 | 4.77 | 0.2899 | -- | 23.41 | 1,064,092.00 | -6.42 | -50.55 | -6.77 | -55.91 | -- | -- | -22.15 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Compass Therapeutics Inc. | 850.00k | -47.76m | 188.50m | 32.00 | -- | 1.36 | -- | 221.76 | -0.3553 | -0.3553 | 0.0063 | 1.01 | 0.0053 | -- | -- | 26,562.50 | -29.93 | -41.75 | -31.25 | -46.41 | -- | -- | -5,618.71 | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
Data as of Nov 21 2024. Currency figures normalised to Kyverna Therapeutics Inc's reporting currency: US Dollar USD
20.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 2.11m | 4.89% |
| Millennium Management LLCas of 30 Sep 2024 | 1.25m | 2.91% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.08m | 2.50% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 981.05k | 2.27% |
| Franklin Advisers, Inc.as of 30 Sep 2024 | 931.86k | 2.16% |
| MBB Capital Partners LLCas of 30 Sep 2024 | 614.48k | 1.42% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 610.10k | 1.41% |
| EcoR1 Capital, LLCas of 30 Sep 2024 | 450.00k | 1.04% |
| Geode Capital Management LLCas of 30 Sep 2024 | 443.31k | 1.03% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 326.19k | 0.76% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
